

## References

### I-223

1. Bardia A, Mayer IA, Diamond JR, et al. Efficacy and safety of anti-trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer. *Journal of Clinical Oncology*. 2017;35(19):2141-2148.
2. Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. *N Engl J Med*. 2019;380:741-751.
3. Ocean AJ, Starodub AN, Bardia A, et al. Sacituzumab govitecan (IMMU-132) an anti-trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics. *Cancer*. 2017;123(19):3843-3854.
4. Trodelvy (sacituzumab govitecan-hziy) for injection, for intravenous use [package insert]. Immunomedics, Inc. Morris Plains, NJ. Revised 02/2023.
5. Clinical Pharmacology™ 2024. Tampa FL: Gold Standard, Inc. Sacituzumab govitecan-hziy.
6. Micromedex DrugDex Compendium®. 2024. Sacituzumab govitecan-hziy.
7. National Comprehensive Cancer Network (NCCN). Sacituzumab govitecan-hziy. NCCN Drugs and Biologics Compendium®. 2024.
8. Tagawa ST, Balar AV, Petrylak DP, Kalebasty AR, et al. TROPHY-U-01: A Phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. *J Clin Oncol*. doi:10.1200/JCO.20.03489.
9. Sacituzumab Govitecan-hziy. In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated July 26, 2021.
10. Bardia A, Hurvitz SA, Tolaney SM, et al; ASCENT Clinical Trial Investigators. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. *N Engl J Med*. 2021;384(16):1529-1541.
11. O'Shaughnessy J, Brufsky A, Rugo HS, et al. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. *Breast Cancer Res Treat*. 2022;195(2):127-139.